Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

Item

http://www.wikidata.org/entity/Q31055613

Q31055613

about

Intermittent versus continuous androgen suppression for prostatic cancer Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer What's New in Prostate Cancer Research? Highlights of GU-ASCO 2015 Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer Hormone naïve prostate cancer: predicting and maximizing response intervals The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK A Urologist's Personal View of Prostate Cancer Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032 The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells Post-treated prostate cancer: normal findings and signs of local relapse on multiparametric magnetic resonance imaging.A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916 Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER.Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit.Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.Predictors of survival outcomes in native sub Saharan black men newly diagnosed with metastatic prostate cancer.Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.Saudi Oncology Society clinical management guidelines for prostate cancer.Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.Risk stratification in the hormonal treatment of patients with prostate cancer Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer An update on the changing indications for androgen deprivation therapy for prostate cancer.SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry.Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy Genetic variants in CASP3, BMP5, and IRS2 genes may influence survival in prostate cancer patients receiving androgen-deprivation therapy

P2860

Q24243575-583AD7CE-B62B-4C9F-B745-649F096921A8 Q26747782-53861AA8-7910-47E2-8ED2-AE5D3EA27383 Q26795625-2BF49963-AB60-4ECF-8AF1-5524D386BB17 Q26801944-6566AB40-EEE8-4759-AFF8-1270D091B3C8 Q26858922-FDF3BB3C-4646-4AD2-86C9-533805996EC8 Q27015904-72B0B320-83DA-4ADD-9705-7F3F0FD20F78 Q27025062-5E561971-D8FE-4E71-A8E3-26A9A6CCFB95 Q28072710-710C3CED-B282-4E7E-BEEE-F99225DE8FCA Q28072919-5D3CE967-40C8-4499-9086-E8A1EA762A1F Q28305717-181E4D75-96B0-418A-9D6F-15F02DDDD7D1 Q28388750-B483E632-AE93-40E8-942A-426F9AA95F62 Q28477278-5FDDA55F-AA46-4641-8EE9-06E0FB9F8684 Q30976248-D6576425-A3F0-4BBC-AD40-FB96459E9D46 Q31140219-7F7DD212-2A34-4327-AD3D-76377F03E0C0 Q33432475-7E611B5E-D3B0-40A8-AEC7-0FDF4FC84E0A Q33898154-17350B1D-A5F3-44FC-BAFF-6A9657042913 Q34032678-4DFA46D6-B2B9-458B-84F0-ACBECD3B037A Q34179268-29FB0665-9EF9-4EF1-AB93-58923B901A9E Q34292169-CDAEE305-AFFE-48D2-826E-AB70811D9CD9 Q34309132-288B48F3-22B9-4429-BD03-AD308F78B28D Q34417941-A4A2B00A-635D-484F-8BFF-1AFB0548F00E Q34437308-44888B0C-456E-4133-9F84-D85947464106 Q34557264-2C5F4F57-80DC-40AC-932C-A038E7D63AE0 Q34566518-A433F7D5-55E3-4A1D-A135-AE85425B9F0B Q34627994-22D56AE4-23D1-4003-B67F-2C33CEDF0580 Q34636636-261C8BE2-A3BF-40FC-BEB2-C76F4CA5C46A Q34637919-76EC8028-D4AB-4265-A9D3-FA6C597B8867 Q34734425-326E8ED6-A795-43CE-A1F9-2C0AA942978C Q34997355-D4E12F5E-6512-45BC-AFF9-4832A496F5C1 Q35070443-274A0DF9-0E9A-4E17-BC16-0584B8FE378E Q35076189-6C11A025-2D94-466F-8DAF-1AB817A95A4D Q35158676-FDEE77A0-911C-4299-AF68-A5D70201C4A7 Q35549863-7EF8F805-11E6-49B5-BC71-E30758BC0B27 Q35563844-46671F42-939D-4E83-8052-60351B37ABA9 Q35656240-7C7B3F34-0619-4286-B30A-ACE2BF150BD3 Q35756538-AD66F8F6-9C3A-4E31-A54B-78FCC0AA6E47 Q35829785-2105C5E2-BC47-4149-BD17-0840A1D35AB8 Q35870468-387F8CBB-5638-4AC3-808D-1FF4C64EE1F8 Q36084404-155733F2-E639-4079-AC9D-D308F045774F Q36109818-D9B8A145-1CBF-45D9-95C9-DE852A12678F

P2860

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

Item

http://www.wikidata.org/entity/Q31055613

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu